Covid-19: Critically ill patients treated with arthritis drug tocilizumab show improved outcomes, researchers report
Jacqui Wise
Abstract
Covid-19: Critically ill patients treated with arthritis drug tocilizumab show improved outcomes, researchers report Jacqui WiseThe rheumatoid arthritis drug tocilizumab seems to improve outcomes in patients with covid-19 who are the most severely ill, show early results released from the Remap-Cap international platform trial.The researchers reported that critically ill patients receiving tocilizumab were more likely to improve than patients who received no immune modulator (odds ratio 1.87)."These are very exciting and encouraging results," said the chief investigator, Anthony Gordon, consultant in intensive care medicine at Imperial College Healthcare NHS Trust, at a Science Media Centre briefing on 19 November. 1 O'Hare R. Arthritis drug effective in treating sickest covid-19 patients.Imperial College London.19 Nov 2020.